Phase II trial to study the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase in relapse after allogeneic stem cell transplantation

Trial Profile

Phase II trial to study the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase in relapse after allogeneic stem cell transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2012

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top